Repare Therapeutics Inc
NASDAQ:RPTX
Balance Sheet
Balance Sheet Decomposition
Repare Therapeutics Inc
Current Assets | 243.7m |
Cash & Short-Term Investments | 223.6m |
Receivables | 15.3m |
Other Current Assets | 4.7m |
Non-Current Assets | 10.2m |
PP&E | 7.5m |
Other Non-Current Assets | 2.7m |
Current Liabilities | 39.1m |
Accounts Payable | 2.4m |
Accrued Liabilities | 26.3m |
Other Current Liabilities | 10.4m |
Non-Current Liabilities | 2.7m |
Other Non-Current Liabilities | 2.7m |
Balance Sheet
Repare Therapeutics Inc
Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|
Assets | |||||||
Cash & Cash Equivalents |
11
|
95
|
326
|
334
|
160
|
111
|
|
Cash Equivalents |
11
|
95
|
326
|
334
|
160
|
111
|
|
Short-Term Investments |
0
|
0
|
8
|
7
|
184
|
112
|
|
Total Receivables |
1
|
3
|
6
|
3
|
4
|
15
|
|
Other Current Assets |
0
|
1
|
7
|
6
|
6
|
5
|
|
Total Current Assets |
12
|
99
|
347
|
351
|
354
|
244
|
|
PP&E Net |
2
|
3
|
9
|
13
|
10
|
8
|
|
PP&E Gross |
2
|
3
|
9
|
13
|
10
|
8
|
|
Accumulated Depreciation |
1
|
1
|
2
|
3
|
5
|
7
|
|
Note Receivable |
0
|
0
|
0
|
0
|
0
|
2
|
|
Other Long-Term Assets |
0
|
1
|
2
|
4
|
1
|
0
|
|
Total Assets |
14
N/A
|
103
+639%
|
357
+248%
|
369
+3%
|
364
-1%
|
254
-30%
|
|
Liabilities | |||||||
Accounts Payable |
1
|
2
|
2
|
2
|
1
|
2
|
|
Accrued Liabilities |
0
|
2
|
7
|
20
|
24
|
26
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
0
|
1
|
2
|
13
|
55
|
10
|
|
Total Current Liabilities |
2
|
4
|
11
|
35
|
79
|
39
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
3
|
9
|
59
|
45
|
6
|
3
|
|
Total Liabilities |
4
N/A
|
13
+191%
|
70
+449%
|
80
+14%
|
85
+5%
|
42
-51%
|
|
Equity | |||||||
Common Stock |
32
|
136
|
384
|
481
|
482
|
483
|
|
Retained Earnings |
23
|
50
|
103
|
210
|
239
|
333
|
|
Additional Paid In Capital |
0
|
4
|
6
|
18
|
37
|
62
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Equity |
10
N/A
|
90
+846%
|
287
+219%
|
288
+1%
|
280
-3%
|
212
-24%
|
|
Total Liabilities & Equity |
14
N/A
|
103
+639%
|
357
+248%
|
369
+3%
|
364
-1%
|
254
-30%
|
|
Shares Outstanding | |||||||
Common Shares Outstanding |
35
|
35
|
37
|
42
|
42
|
42
|